St. Wendel, Germany

Joerg Dreyhsig

This inventor holds 1 USPTO granted patent. Top assignee: Fresenius Medical Care Deutschland Gmbh. Active years: 2012.


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Joerg Dreyhsig: Innovator in Blood Treatment Technology

Introduction

Joerg Dreyhsig is a notable inventor based in St. Wendel, Germany. He has made significant contributions to the field of medical technology, particularly in the area of blood treatment. His innovative approach has led to the development of a patented method that enhances the safety and efficiency of extracorporeal blood treatments.

Latest Patents

Dreyhsig holds a patent for a "Method and apparatus for monitoring the supply of replacement fluid during an extracorporeal treatment of blood." This invention focuses on the detection of replacement fluid supply, utilizing measurements of the optical or physical density of blood or its constituents in the extracorporeal circulation. The method allows for adjustments in blood flow rates and replacement rates, ensuring accurate monitoring during treatment.

Career Highlights

Joerg Dreyhsig is associated with Fresenius Medical Care Deutschland GmbH, a leading company in the field of medical devices and services for individuals with renal diseases. His work at this organization has been pivotal in advancing technologies that improve patient care and treatment outcomes.

Collaborations

Dreyhsig collaborates with Joachim Noack, contributing to the development of innovative solutions in the medical field. Their partnership exemplifies the importance of teamwork in driving technological advancements.

Conclusion

Joerg Dreyhsig's contributions to blood treatment technology through his patented methods demonstrate his commitment to improving healthcare. His work continues to influence the medical industry, ensuring better patient outcomes in extracorporeal treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…